CUE Cue Biopharma

Watchlist

3.350

-0.070-2.05%

Trading Session 02/01 14:39 ET

High

3.530

Open

3.330

Turnover

219.87K

Low

3.300

Pre Close

3.420

Volume

64.63K

Intraday

Price Forecast

Comment

Announcement

Cue Biopharma to Present at Two February 2023 Scientific Conferences
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and mod
02-01 08:06 ET
Cue Biopharma names Matteo Levisetti as New Chief Medical Officer
01-23 08:20 ET
Cue Biopharma, Inc. (NASDAQ:CUE) Sees Large Decrease in Short Interest
Cue Biopharma, Inc. (NASDAQ:CUE – Get Rating) was the target of a significant drop in short interest in December. As of December 30th, there was short interest totalling 592,200 shares, a drop of 17
01-21 08:21 ET
Cue Biopharma, Inc. (NASDAQ:CUE) Sees Large Decline in Short Interest
Cue Biopharma, Inc. (NASDAQ:CUE – Get Rating) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 717,000 shares, a decline of 5.6
01-04 03:51 ET
Newbridge Financial Services Group Inc. Acquires 5,000 Shares of Cue Biopharma, Inc. (NASDAQ:CUE)
Newbridge Financial Services Group Inc. grew its holdings in shares of Cue Biopharma, Inc. (NASDAQ:CUE – Get Rating) by 41.7% during the third quarter, according to the company in its most recent fi
12-22-2022 05:12:00 ET
Cue Biopharma, Inc. (NASDAQ:CUE) Sees Large Drop in Short Interest
Cue Biopharma, Inc. (NASDAQ:CUE – Get Rating) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 872,100 shares, a drop of 29
12-01-2022 10:31:53 ET
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and mod
11-22-2022 08:07:03 ET
Cue Biopharma Price Target Announced at $7.00/Share by Piper Sandler
Cue Biopharma Price Target Announced at $7.00/Share by Piper Sandler
11-21-2022 05:18:13 ET
Cue Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/21/2022 117.39% Piper Sandler → $7 Initiates Coverage On → Overweight 08/24/2022 210.56% Oppenheimer $2
11-21-2022 05:08:38 ET
Piper Sandler Initiates Coverage On Cue Biopharma With Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Edward Tenthoff initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Overweight rating and announces Price Target of $7.
11-21-2022 05:08:20 ET

Company Overview More

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

CEO： Mr. Daniel R. Passeri

Market： NASDAQ

Listing Date： 01/02/2018

Paper Trade More

Direction

Buy

Sell

Types

LMT Order

Price

QTY

Amount

Get Started

Hot List

TradeSearchNews

SymbolLatest price%Chg

Watchlist